RE:RE:RE:RE:RE:Hmm...(Google Translated) from Canaria Bio (Two items)
1.
https://canariabio.com/ir/notice/?uid=86&mod=document&pageid=1
Notice to shareholders and stakeholders
Posted bycanariabioPosted on 2022-09-05 11:23
Hello shareholders and stakeholders,
As the media recently reported on the acquisitions of listed companies by Edison Motors and investment associations since June last year, it was reported that certain forces involved in stock price manipulation had been involved in the acquisition of other listed companies, including Canary Bio (formerly Hyundai Feed). Since then, malicious rumors about the company and its affiliates have been circulating until recently, and the stock price of the company seems to have been affected, such as a decline.
However, the company is not the subject of investigation of stock price manipulation and unfair trade. We have never done anything that violates the law. Unless the alleged crime is embezzlement and breach of trust, there is no chance that rumors of “trading suspension” and “delisting” that are floating around in the market will come true. If there was any unfair trade using inside information, the company will thoroughly disclose it and file a complaint with the prosecution.
We will always humbly accept the warm interest from our shareholders and related parties, and we will continue to become executives and employees who prioritize sustainable growth through the stable operation of the existing feed business and the success of the new bio business.
thank you
Canary Bio Co., Ltd.
CEO Na Han-ik
2.
https://canariabio.com/ir/notice/?uid=87&mod=document&pageid=1
FACT Check series 1:
Rumor: Canary Bio's phase 3 clinical trial has already been halted, but the company is hiding it.
FACT:
This is a very malicious rumor and is not true. Currently, patient recruitment for phase 3 clinical trials is continuing, and additional clinical sites are being opened. Currently, from 152 sites, an additional 20 sites are being prepared. If the DSMB (Data Stability Monitoring Committee) finds a problem and recommends discontinuing the clinical trial, the company must immediately disclose it. Also, it's impossible to hide the clinical suspension status because you have to report this to the FDA.
As of September 4, 2022, 379 (63%) of 602 patients have been recruited. As of August 21st, the number of patients recruited was 361 (60%).
Cohort 1, which proceeds with adjuvant chemotherapy after surgery, aims to recruit a total of 372 people. Of these, 15% were expected to drop out, and it was expected that the final number would be 316. Currently, the dropout rate is 10%, which is good. Interim futility assessments are made when the disease relapse event occurred in 117 patients (37% of the final number). The final outcome analysis was done when the event occurred in 232 patients (73% of the final number of patients). Considering that the progression-free survival period was 12 months when only paclitaxel and carboplatin, which are the existing standard treatments, were used in Phase 2 clinical trials, interim results are expected in the 3Q of 2023 as expected. In addition, it is expected that the final result will be seen at the end of 2024, but if the clinical trial continues otherwise, 232 patients have no event, which can be considered a good prognosis. This is because it is difficult to expect a progression-free survival period of more than 24 months with only chemotherapy alone.
Cohort 2, which proceeds with Neoadjuvant Chemotherapy before surgery, aims to recruit a total of 230 people. Of these, 15% were expected to drop out, and it was expected that the final number would be 195. Currently, the dropout rate is 10%, which is good. Interim futility assessments are made when the event occurred in 83 patients (43% of the final number). The final outcome analysis is done when the event occurs in 165 patients (85% of the final number of patients). Because patients with more severe disease are more likely to receive neoadjuvant chemotherapy, the progression-free survival is expected to be shorter than that of adjuvant chemotherapy. The timing of the results is not expected to differ significantly.
Canary Bio is doing its best to recruit patients, risking life and death for this global clinical phase 3 clinical trial. Thank you for your interest in this clinical trial in the Korean medical community. It's a little late, but in addition to the existing 8 sites in Korea, Samsung Seoul and Korea University Guro Hospital announced their intention to participate in our clinical trial at the American Cancer Society in June. We expect to be able to start recruiting patients at these two hospitals soon. Also, Professor Choi Jong-kwon of Konyang University can receive oregobumab for the last time for patients who can no longer be treated.
He prepared an emergency clinical trial to pave the way, and recently received approval from the Ministry of Food and Drug Safety. With a lot of interest, we promise to do our best to make oregobomab hope for ovarian cancer patients. If malicious rumors make the company difficult and difficult to finance, oregobomab, which can be a hope for ovarian cancer patients, cannot be released. Please do not view our company as a stock, but remember that it is a matter of life and death for ovarian cancer patients. For the success of the Korean bio industry and the company's success, we would be grateful if shareholders would not be swayed by malicious rumors and wait for Oregobomab to become a global blockbuster.
Take away:
Rumor do not match what s here: https://clinicaltrials.gov/ct2/show/NCT04498117#contacts
However, the decline in CanariaBio stock price ultimately impact the valuation of QPT.V
https://www.google.com/finance/quote/016790:KOSDAQ? (select 1M and you'll see).
Have to wonder if the 10 years expiry date on the recent optons are related to this?
Continued silence from QPT.V on events with CanatiaBio does not help!
How does this "add value to shareholders"?